S&P 500 index data: S&P 500 Copyright ©
All data supplied by Morningstar Real-Time Data. U.S. intraday real-time exchange quotes are sourced from BATS when available. End-of-day quotes for Nasdaq, NYSE, and Amex securities will appear 15 minutes after close. Graph times are Eastern Standard. © Copyright Morningstar, Inc .
|Start Premium Trial||Register For Free|
|P||F||Fund Financial Data (13,000+ funds)|
|P||F||Stock Financial Data (7,000+ stocks)|
|P||F||Stock and Fund Screeners (basic)|
|P||F||Investing Articles and Market Commentary|
|P||F||Articles Archive (>30 days)|
|P||F||Discuss (dozens of stock, fund, bond, and general bulletin boards)|
|P||F||Portfolio Manager (basic)|
|P||F||Morningstar Investment Classroom|
|P||F||Morningstar Investing Classroom Rewards (earn as you learn and redeem for Morningstar merchandise)|
|P||Morningstar Fund Analyst Reports (full research on 2,000 funds and ETFs)|
|P||Morningstar Stock Analyst Reports (full research on 2,000 stocks)|
|P||Morningstar Stock and Fund Stewardship Grades|
|P||Portfolio Manager (advanced with 10 x-ray analyses, including guidance)|
|P||Portfolio Monitor (monthly and on-demand personalized portfolio statements)|
|P||Morningstar Proprietary Stock Information (stock star ratings, buy/sell prices, economic moat ratings, and more)|
|P||Morningstar Stock and Fund Favorites & Red Flags eNewsletters|
|P||Premium Stock and Fund Screeners (advanced with nearly infinite ways to find the best securities for you)|
|P||Discounts on Morningstar newsletters, books, seminars, and more|
Access these features and more when you sign up for Free Membership.
Join Morningstar today. It's Free.
Access these features and more when you sign up for Premium Membership.
Start your free 14-day trial today online
Your subscription may be tax deductible. Please contact your tax advisor.
|Emergent BioSolutions Reports Financial Results for Fourth Quarter and Full Year 2012 (2013/3/7)|
|Emergent BioSolutions Participates in NATO Defense against Terrorism Workshop at the Counter Terror Expo in London (2013/4/30)|
|Emergent BioSolutions Reports Financial Results for First Quarter 2013 (2013/5/2)|
|Emergent BioSolutions Announces Positive Preclinical Efficacy and PK Data for Its New Bispecific Adaptir Protein Therapeutic ES414 at AACR (2013/4/11)|
|Emergent BioSolutions Presents Efficacy Data on ES210; a Bispecific ADAPTIR Molecule for Treating Autoimmune Diseases (2013/4/11)|
|Emergent BioSolutions to Webcast Presentation at Credit Suisse First Annual Antibody Day (2013/4/29)|
|Emergent BioSolutions to Acquire Healthcare Protective Products Division of Bracco Diagnostics Inc. (2013/4/25)|
|Emergent BioSolutions to Expand Front Line CLL Clinical Trial of TRU-016 and Rituximab Based on Strong Patient Enrollment and Encouraging Early Clinical Data (2013/4/5)|
|Emergent BioSolutions Presents Preclinical Efficacy Data on ES414 Its Lead ADAPTIR Bispecific Therapeutic for Prostate Cancer (2013/5/3)|
|Emergent BioSolutions to Release Fourth Quarter and Full Year 2012 Financial Results and Conduct a Conference Call on March 7, 2013 (2013/2/1)|
Click above to view more mutual fund data and stats for ebs - Emergent BioSolutions, Inc..